Excessive transcription-replication conflicts are a vulnerability of BRCA1-mutant cancers.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
22 05 2023
Historique:
accepted: 14 03 2023
revised: 17 02 2023
received: 31 05 2022
medline: 23 5 2023
pubmed: 18 3 2023
entrez: 17 3 2023
Statut: ppublish

Résumé

BRCA1 mutations are associated with increased breast and ovarian cancer risk. BRCA1-mutant tumors are high-grade, recurrent, and often become resistant to standard therapies. Herein, we performed a targeted CRISPR-Cas9 screen and identified MEPCE, a methylphosphate capping enzyme, as a synthetic lethal interactor of BRCA1. Mechanistically, we demonstrate that depletion of MEPCE in a BRCA1-deficient setting led to dysregulated RNA polymerase II (RNAPII) promoter-proximal pausing, R-loop accumulation, and replication stress, contributing to transcription-replication collisions. These collisions compromise genomic integrity resulting in loss of viability of BRCA1-deficient cells. We also extend these findings to another RNAPII-regulating factor, PAF1. This study identifies a new class of synthetic lethal partners of BRCA1 that exploit the RNAPII pausing regulation and highlight the untapped potential of transcription-replication collision-inducing factors as unique potential therapeutic targets for treating cancers associated with BRCA1 mutations.

Identifiants

pubmed: 36928661
pii: 7079642
doi: 10.1093/nar/gkad172
pmc: PMC10201440
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
PAF1 protein, human 0
RNA Polymerase II EC 2.7.7.-
MePCE protein, human EC 2.1.1.-
Methyltransferases EC 2.1.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4341-4362

Subventions

Organisme : Cancer Research UK
ID : C17183/A23303
Pays : United Kingdom

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.

Références

Cancer Res. 2016 May 1;76(9):2778-90
pubmed: 27197267
J Biol Chem. 2013 Jul 19;288(29):21173-21183
pubmed: 23744076
Blood. 2021 Apr 22;137(16):2171-2181
pubmed: 33270841
Oncogene. 2021 Apr;40(17):3001-3014
pubmed: 33716297
Nat Commun. 2017 Jun 26;8:15908
pubmed: 28649985
Mutat Res Genet Toxicol Environ Mutagen. 2022 Apr-May;876-877:503450
pubmed: 35483781
Cancer Genet. 2015 May;208(5):237-40
pubmed: 25800897
Cell Rep. 2018 Jan 23;22(4):1031-1039
pubmed: 29386125
Genes Dev. 2014 Jul 1;28(13):1384-96
pubmed: 24990962
Nat Chem Biol. 2019 Feb;15(2):132-140
pubmed: 30559425
J Biol Chem. 2001 Aug 24;276(34):31793-9
pubmed: 11431468
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
DNA Repair (Amst). 2014 Jul;19:84-94
pubmed: 24746923
Mol Cell. 2007 Jul 20;27(2):262-274
pubmed: 17643375
Cell Rep. 2016 Jun 14;15(11):2488-99
pubmed: 27264184
Transcription. 2019 Apr;10(2):57-75
pubmed: 30227759
J Cell Biol. 2021 Sep 6;220(9):
pubmed: 34232287
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Trends Genet. 2019 Oct;35(10):724-733
pubmed: 31358304
Nucleic Acids Res. 2010 Jan;38(2):360-9
pubmed: 19906723
Molecules. 2019 Oct 27;24(21):
pubmed: 31717862
Aging Cell. 2006 Apr;5(2):187-95
pubmed: 16626397
Annu Rev Genet. 2013;47:483-508
pubmed: 24050178
Nat Rev Mol Cell Biol. 2017 Apr;18(4):263-273
pubmed: 28248323
Genes Dev. 2003 Jun 1;17(11):1402-14
pubmed: 12782658
Cancers (Basel). 2021 Dec 27;14(1):
pubmed: 35008272
Mol Cell. 2012 Apr 27;46(2):115-24
pubmed: 22541554
Prz Menopauzalny. 2016 Dec;15(4):215-219
pubmed: 28250726
Nature. 2015 Feb 12;518(7538):258-62
pubmed: 25642963
Proc Natl Acad Sci U S A. 2009 May 12;106(19):7798-803
pubmed: 19416841
Mol Cell. 2015 Feb 19;57(4):636-647
pubmed: 25699710
Nature. 2001 Nov 15;414(6861):322-5
pubmed: 11713533
J Breast Cancer. 2019 Jan 22;22(1):1-14
pubmed: 30941229
Clin Epigenetics. 2019 May 16;11(1):81
pubmed: 31097014
Cell Rep. 2018 Feb 6;22(6):1374-1383
pubmed: 29425494
Trends Biotechnol. 2019 Jan;37(1):38-55
pubmed: 30177380
Br J Pharmacol. 2014 Jan;171(1):55-68
pubmed: 24102143
Genes Dev. 2011 Oct 1;25(19):2041-56
pubmed: 21979917
Cell. 2015 Aug 27;162(5):1003-15
pubmed: 26279188
J Clin Invest. 2021 Feb 1;131(3):
pubmed: 33529165
Nat Struct Mol Biol. 2017 May 4;24(5):439-443
pubmed: 28471430
Nature. 2001 Nov 15;414(6861):317-22
pubmed: 11713532
Trends Cell Biol. 2019 Oct;29(10):820-834
pubmed: 31421928
Transcription. 2011 May;2(3):103-108
pubmed: 21922053
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Nat Struct Mol Biol. 2014 Apr;21(4):366-74
pubmed: 24658350
Mol Cell. 2003 Oct;12(4):971-82
pubmed: 14580347
Transcription. 2018;9(2):95-101
pubmed: 28820318
Interdiscip Top Gerontol. 2014;39:45-61
pubmed: 24862014
Nat Cell Biol. 2014 Jan;16(1):2-9
pubmed: 24366029
Cancer. 2015 Jan 15;121(2):269-75
pubmed: 25224030
Nature. 2020 Sep;585(7824):298-302
pubmed: 32669707

Auteurs

Parasvi S Patel (PS)

Princess Margaret Cancer Centre, University Health Network, Toronto, OntarioM5G 1L7, Canada.
Department of Medical Biophysics, University of Toronto, OntarioM5G 1L7, Canada.

Arash Algouneh (A)

Princess Margaret Cancer Centre, University Health Network, Toronto, OntarioM5G 1L7, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, OntarioM5S 1A8, Canada.

Rehna Krishnan (R)

Princess Margaret Cancer Centre, University Health Network, Toronto, OntarioM5G 1L7, Canada.

John J Reynolds (JJ)

Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

Kevin C J Nixon (KCJ)

Princess Margaret Cancer Centre, University Health Network, Toronto, OntarioM5G 1L7, Canada.

Jun Hao (J)

Princess Margaret Cancer Centre, University Health Network, Toronto, OntarioM5G 1L7, Canada.

Jihoon Lee (J)

Department of Cell and Systems Biology, University of Toronto, OntarioM5S 3G5, Canada.

Yue Feng (Y)

Princess Margaret Cancer Centre, University Health Network, Toronto, OntarioM5G 1L7, Canada.
Department of Medical Biophysics, University of Toronto, OntarioM5G 1L7, Canada.

Chehronai Fozil (C)

Princess Margaret Cancer Centre, University Health Network, Toronto, OntarioM5G 1L7, Canada.

Mia Stanic (M)

Department of Medical Biophysics, University of Toronto, OntarioM5G 1L7, Canada.

Talya Yerlici (T)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, OntarioM5S 1A8, Canada.

Peiran Su (P)

Princess Margaret Cancer Centre, University Health Network, Toronto, OntarioM5G 1L7, Canada.
Department of Medical Biophysics, University of Toronto, OntarioM5G 1L7, Canada.

Fraser Soares (F)

Princess Margaret Cancer Centre, University Health Network, Toronto, OntarioM5G 1L7, Canada.

Elisabeth Liedtke (E)

Princess Margaret Cancer Centre, University Health Network, Toronto, OntarioM5G 1L7, Canada.
Department of Medical Biophysics, University of Toronto, OntarioM5G 1L7, Canada.

Gil Prive (G)

Princess Margaret Cancer Centre, University Health Network, Toronto, OntarioM5G 1L7, Canada.

Gary D Baider (GD)

Terrence Donnelly Centre for Cellular and Biomedical Research, University of Toronto, Toronto, ON, Canada.

Miquel Angel Pujana (MA)

Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain.

Karim Mekhail (K)

Department of Medical Biophysics, University of Toronto, OntarioM5G 1L7, Canada.

Housheng Hansen He (HH)

Princess Margaret Cancer Centre, University Health Network, Toronto, OntarioM5G 1L7, Canada.
Department of Medical Biophysics, University of Toronto, OntarioM5G 1L7, Canada.

Anne Hakem (A)

Princess Margaret Cancer Centre, University Health Network, Toronto, OntarioM5G 1L7, Canada.

Grant S Stewart (GS)

Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

Razqallah Hakem (R)

Princess Margaret Cancer Centre, University Health Network, Toronto, OntarioM5G 1L7, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, OntarioM5S 1A8, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH